Gilead Sciences Inc. (GILD) Net income fell to 2.71 billion: Growth Analysis

Gilead Sciences Inc. (GILD) is owned by a number of high-value investors. Its largest direct holder is Gayle E. Wilson Independent Director with 126,782 shares. The second-largest direct holder is Per Wold-olsen Independent Director, with 97,854 shares of the company’s stock. In third place with 64,859 shares of GILD is Kevin E. Lofton Independent Director.

Now turning to institutional ownership of Gilead Sciences Inc. (GILD), The Vanguard Group, Inc. is the top holder with 100.71 million shares. The next largest fund holder of this company’s stock is Capital Research & Management Co. (Global Investors) with 76.79 million shares. In the third-place spot with 65.86 million shares is BlackRock Fund Advisors.

This company’s stock price was $66.07 at the previous market close, with its latest volume reaching 5333340. Compare that to its average daily volume of 6.07M. Given the fact that this stock has 1.26B shares outstanding, its current market value is sitting at $83.44B. This publicly-traded stock’s 60-month Beta is 1.14. Its Price to Sales ratio is 3.73, its Price to Cash Flow ratio is 3.65, and its Price to Book ratio is 4.06.

GILD stock has achieved a 5-day range of $65.17 to $67.52, with a total performance of -1.80% during that period. Meanwhile, in the past month of trading, this stock has traded in the range of $62.38 to $67.65, generating a +2.18% change during the period. In the past three months, this stock’s price has changed by +4.92%, trading in the range of $60.89 to $68.16.

In the past 5 days, shares of GILD have made a new high 2 times. In the last month, it has made a new high 4 times, and in the past 3 months, it has made a new high 6 times.

Now let’s turn to this public company’s earnings. For the quarter ending 9/29/2019, the earnings per share (EPS) was reported at 1.75. This is a 0.01 difference compared to the consensus estimate of 1.74, amounting to an earnings surprise of 0.60%. In the previous quarter, which ended in 9/29/2019, the consensus estimate was 1.72, making for an earnings surprise of 5.80%. For the quarter ending 3/30/2019, EPS was reported at 1.76, generating a 9.30% earnings surprise.

The Net Income for the most recent full fiscal year, which ended in 12-2018, was $5.46 billion. This is compared to the prior year, where Net Income was $4.64 billion. Meanwhile, this company’s Operating Cash Flow was $8.4 billion for the year, compared to $11.9 billion in 2017. Capital Expenditures for the year were reportedly -$924.0 million, compared to -$590.0 million, and Free Cash flow was $7.48 billion compared to the prior year’s $11.31 billion.

Gilead Sciences Inc. (GILD) stock currently has a Financial Strength score of 5/10. This is due to a combination of factors, including a Cash to Debt ratio of 0.93, an Equity to Asset ratio of 0.35, a Debt to Equity ratio of 1.19 and a Debt to EBITDA of 3.67. The Interest Coverage of this stock is 4.3, its Piotroski F-Score is 7, its Altman Z-Score is 2.78 and its Beneish M-Score is -3.02.

This publicly-traded company’s Profitability and Growth score is 10/10, thanks to a combination of things: an Operating Margin of 19.4, a Net Margin of 12.04, a ROE of 12.31, and a ROC of 128.63.

Shifting focus now to Valuation and Return for GILD, this company’s Price to Tangible Book is 51.62 and its Price to Median PS Value is 0.86. Price to Peter Lynch Fair Value for GILD is now 0.00, and this organization’s Price to Graham Number is 8.5. Meanwhile, its Forward Rate of Return (Yactman) is 4.47.

Certain ratios provide helpful insights into how a stock is performing. The Quick Ratio for GILD is sitting at 2.87, while its Current Ratio is 2.96 and its PEG Ratio is 1.84. This stock’s PB Ratio is 4.05, its PS Ratio is 3.77, its Forward PE Ratio is 9.31, and its PE Ratio without NRI is 31.62. Similarly, its Shiller PE Ratio is 13.28, its Price to Owner Earnings is 38.8, its Price to Free Cash Flow is 10.51 and its Price to Operating Cash Flow is 9.47.